[Clinical aspects and treatment of primary focal segmental glomerulosclerosis and hyalinosis].
The authors studied the clinico-laboratory values and efficacy of pathogenetic treatment in 8 patients with primary segmental glomerulosclerosis and hyalinosis (PSGH). The disease is characterized by distinct disorders in the T-system immunity. Glucocorticoid treatment did not essentially effect the course of PSGH. Cyclophosphane treatment allowed to achieve essential stable clinical improvement in certain patients.
Diadyk
A I
AI
Vasilenko
I V
IV
Shpilevaia
N I
NI
Siniachenko
O V
OV
Kobets
V G
VG
D000293:Adolescent; D000328:Adult; D001707:Biopsy, Needle; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000175:diagnosis*; D005923:Glomerulosclerosis, Focal Segmental / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D011239:Prednisolone / Q000627:therapeutic use
D003520:Cyclophosphamide; D011239:Prednisolone
Klinika i lechenie pervichnogo fokal'nogo segmentarnogo glomeruloskleroza i gialinoza.